Aspirin thromboprophylaxis in joint replacement surgery.

Autor: Sharda AV; Division of Hematology Beth Israel Deaconess Medical Center Boston Massachusetts USA.; Division of Hematology New England Baptist Hospital Boston Massachusetts USA., Fatovic K; Research Division New England Baptist Hospital Boston Massachusetts USA., Bauer KA; Division of Hematology Beth Israel Deaconess Medical Center Boston Massachusetts USA.; Division of Hematology New England Baptist Hospital Boston Massachusetts USA.
Jazyk: angličtina
Zdroj: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2022 Jan 24; Vol. 6 (1), pp. e12649. Date of Electronic Publication: 2022 Jan 24 (Print Publication: 2022).
DOI: 10.1002/rth2.12649
Abstrakt: Background: Aspirin is commonly used as the only pharmacologic agent for prevention of venous thromboembolism (VTE) after joint replacement surgery in the United States. Despite this, prospective studies investigating VTE events after aspirin-only thromboprophylaxis in joint replacement surgery are lacking in the real-world setting.
Objectives: The aim of this study was to estimate the risk of VTE with aspirin-only pharmacologic prophylaxis following joint replacement surgery.
Methods: We carried out a prospective observational study of 350 low-risk patients (no prior history of VTE and low cardiovascular risk factors) who underwent total knee and total hip arthroplasty and received only aspirin for thromboprophylaxis postoperatively.
Results: The observed risk of symptomatic VTE was 1.7% (95% confidence interval, 0.9%-3.3%) over 3 months of follow up, with only one major bleeding event and no surgical hematomas.
Conclusion: The risk of VTE with aspirin monotherapy for thromboprophylaxis in joint replacement surgery in this real-world cohort was higher than previously reported.
(© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)
Databáze: MEDLINE